Monthly Archives: January 2018

http://www.lslog.com/pfizers-prevnar-posts-1-53b-in-q4-sales-handily-beating-consensus/Pfizer's Prevnar posts $1.53B in Q4 sales, handily beating consensus

Pfizer's Prevnar posts $1.53B in Q4 sales, handily beating consensus

Pfizer’s Prevnar posts .53B in Q4 sales, handily beating consensus Pfizer’s Prevnar turned in consensus-beating sales of $1.53 billion—up 7% over the same period last year—thanks to government purchases internationally […]

http://www.lslog.com/repairing-mutation-clusters-with-crispr-could-lead-to-broader-duchenne-therapy/Repairing mutation ‘clusters’ with CRISPR could lead to broader Duchenne therapy

Repairing mutation ‘clusters’ with CRISPR could lead to broader Duchenne therapy

Repairing mutation ‘clusters’ with CRISPR could lead to broader Duchenne therapy Targeting “clusters” of mutations in the dystrophin gene could lead to a treatment for as many as 60% of […]

http://www.lslog.com/pfizer-pats-itself-on-the-back-for-tax-reform-lobbying-do-gooder-investments/Pfizer pats itself on the back for tax reform lobbying, do-gooder investments

Pfizer pats itself on the back for tax reform lobbying, do-gooder investments

Pfizer pats itself on the back for tax reform lobbying, do-gooder investments On Pfizer’s fourth-quarter conference call, Morgan Stanley analyst David Risinger congratulated company executives on their “efforts to educate […]

http://www.lslog.com/sage-expands-into-sleep-disorders-after-early-phase-success/Sage expands into sleep disorders after early-phase success

Sage expands into sleep disorders after early-phase success

Sage expands into sleep disorders after early-phase success Sage Therapeutics has added sleep disorders to the list of indications targeted by SAGE-217. The CNS specialist committed to initiating sleep disorder […]

http://www.lslog.com/what-will-pfizer-do-with-tax-reform-it-wont-revive-a-split-cfo-says/What will Pfizer do with tax reform? It won't revive a split, CFO says

What will Pfizer do with tax reform? It won't revive a split, CFO says

What will Pfizer do with tax reform? It won’t revive a split, CFO says Pfizer’s finally getting what it always wanted in U.S. tax reform. And now, all eyes are […]

http://www.lslog.com/roches-pricey-new-hemophilia-drug-hemlibra-gets-a-rare-blessing-from-u-s-cost-watchdogs/Roche's pricey new hemophilia drug Hemlibra gets a rare blessing from U.S. cost watchdogs

Roche's pricey new hemophilia drug Hemlibra gets a rare blessing from U.S. cost watchdogs

Roche’s pricey new hemophilia drug Hemlibra gets a rare blessing from U.S. cost watchdogs As the hemophilia market gets increasingly crowded, Roche needs all the help it can get generating […]

http://www.lslog.com/pfizer-confirms-neuro-cuts-as-it-swings-the-ax-on-a-host-of-other-early-projects/Pfizer confirms neuro cuts as it swings the ax on a host of other early projects

Pfizer confirms neuro cuts as it swings the ax on a host of other early projects

Pfizer confirms neuro cuts as it swings the ax on a host of other early projects Pfizer already forewarned that it was cutting jobs and projects out of its neuro […]

http://www.lslog.com/ema-to-lose-50-of-its-floor-space-in-move-to-temporary-amsterdam-home/EMA to lose 50% of its floor space in move to temporary Amsterdam home

EMA to lose 50% of its floor space in move to temporary Amsterdam home

EMA to lose 50% of its floor space in move to temporary Amsterdam home The European Medicines Agency (EMA) will move into temporary accommodations half the size of its current […]

http://www.lslog.com/sanofi-expands-u-s-biologics-plant-even-as-it-strikes-deals-to-stuff-its-pipeline/Sanofi expands U.S. biologics plant even as it strikes deals to stuff its pipeline

Sanofi expands U.S. biologics plant even as it strikes deals to stuff its pipeline

Sanofi expands U.S. biologics plant even as it strikes deals to stuff its pipeline Sanofi, which has been converting its biologics plant in Framingham, Massachusetts, to digital manufacturing, will again […]

http://www.lslog.com/sec-sues-over-suspected-insider-trading-around-sanofis-bioverativ-buy/SEC sues over suspected insider trading around Sanofi's Bioverativ buy

SEC sues over suspected insider trading around Sanofi's Bioverativ buy

SEC sues over suspected insider trading around Sanofi’s Bioverativ buy Did insider trading occur around Sanofi’s $11.6 billion deal for Bioverativ? The Securities and Exchange Commission thinks it may have—and […]